™
What’s next is already taking shape
At EmeraNova, progress happens through new technologies, new partnerships, new evidence, and new possibilities for where tissue restoration can make a difference. We’re working with clinicians, innovators, and partners to bring promising solutions into new care settings—and help ensure the people who can benefit from what’s next know it’s coming.
Follow our latest news as we bring what’s next to life.
BioLab Holdings Adds FastSkin® Autologous Wound Care Technology to Tissue Restoration Portfolio
Expanding the wound care toolbox with an autologous option.
Press releaseBioLab Holdings Achieves AATB Accreditation
Milestone reflects commitment to quality, safety, and operational excellence while supporting future growth
Press releaseBioLab Holdings Provides Clinical Trial Updates Across CAMP Platform and Emerging Technologies
Company advances multiple trials evaluating wound care innovations and imaging technologies
Press releaseBioLab Holdings Announces Strategic Partnership with Sweet Bio® to Expand Continuum of Wound Care Solutions
The collaboration is intended to accelerate access to the APIS® bioengineered wound products and support broader adoption among clinicians across care settings.
Press releaseBioLab Holdings Earns Great Place to Work® Certification
Qualification Demonstrates Commitment to People, Purpose and Performance
Press releaseBioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial -Tissue Regeneration Solutions
The partnership allows BioLab to differentiate its skin substitute portfolio, with a focus on the physician office setting, to better align with the varying clinical requirements across the continuum of wound care.
Press releaseBioLab Holdings Announces Significant Team Growth Across Key Departments
Hiring Growth Reflects Commitment to Research, Quality and Compliance
Press releaseBioLab Holdings Inc. Announces Multiple Clinical Trials to Advance Chronic Wound Care
BioLab Holdings, Inc. a Phoenix-based medical manufacturer specializing in wound care solutions, announced the ongoing development of several clinical trials designed to demonstrate the efficacy and safety of its Cellular, Acellular, and Matrix-like Products (CAMPs) in covering and protecting, non-healing wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
Press releaseBioLab Holdings, Inc. Announces Investment in Cold Atmospheric Plasma Technology
Partnership Will Advance Portable Antimicrobial Solutions for Wound Care and Dermatology
StoryASU students gain new opportunities from $2.2M BioLab gift
Alumni-founded BioLab Holdings invests in creation of state-of-the-art learning opportunities at W. P. Carey School of Business
Press releaseBioLab Holdings, Inc. Announces Strategic Investment in AI Diagnostic Technology
BioLab Holdings, Inc is proud to announce its strategic investment and commercialization partnership with cureVision, a breakthrough digital wound care company.
Press releaseBioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management
Press releaseBioLab Holdings, Inc. Launches Multicenter Clinical Trial to Evaluate Amnion Grafts for Chronic Wounds
Study Will Assess Real-World Effectiveness of Tri-Layer and Single-Layer Amnion Grafts in Treating Diabetic Foot and Venous Leg Ulcers
Press releaseBioLab Holdings, Inc. Announces Medical Advisory Board
Distinguished Wound Care Specialists to Provide Invaluable Insights Across BioLab’s Operations
Press releaseBioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH
Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen
Press releaseBioLab Holdings, Inc. Receives IRB Approval for Trial on Membrane Wrap™
Study will Evaluate Efficacy of Skin Substitute on Venous Leg Ulcers